NO20042926L - Indolinonderivater nyttige sorn proteinkinaseinhibitorer - Google Patents

Indolinonderivater nyttige sorn proteinkinaseinhibitorer

Info

Publication number
NO20042926L
NO20042926L NO20042926A NO20042926A NO20042926L NO 20042926 L NO20042926 L NO 20042926L NO 20042926 A NO20042926 A NO 20042926A NO 20042926 A NO20042926 A NO 20042926A NO 20042926 L NO20042926 L NO 20042926L
Authority
NO
Norway
Prior art keywords
sup
kinase inhibitors
protein kinase
derivatives useful
indolinone derivatives
Prior art date
Application number
NO20042926A
Other languages
English (en)
Other versions
NO327550B1 (no
Inventor
John H Griffin
Roger Briesewitz
Jonathan W Wray
Original Assignee
Theravance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Inc filed Critical Theravance Inc
Publication of NO20042926L publication Critical patent/NO20042926L/no
Publication of NO327550B1 publication Critical patent/NO327550B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
NO20042926A 2001-12-27 2004-07-08 Indolinonderivater,fremgangsmate for fremstilling derav, farmasoytiske preparater samt anvendelse av forbindelsene NO327550B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34374601P 2001-12-27 2001-12-27
US34381301P 2001-12-27 2001-12-27
PCT/US2002/041252 WO2003057690A1 (en) 2001-12-27 2002-12-20 Indolinone derivatives useful as protein kinase inhibitors

Publications (2)

Publication Number Publication Date
NO20042926L true NO20042926L (no) 2004-07-08
NO327550B1 NO327550B1 (no) 2009-08-10

Family

ID=26993599

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20042926A NO327550B1 (no) 2001-12-27 2004-07-08 Indolinonderivater,fremgangsmate for fremstilling derav, farmasoytiske preparater samt anvendelse av forbindelsene

Country Status (22)

Country Link
US (3) US6686362B2 (no)
EP (1) EP1458713B1 (no)
JP (1) JP4363985B2 (no)
KR (1) KR100965519B1 (no)
CN (1) CN1290844C (no)
AT (1) ATE302771T1 (no)
AU (1) AU2002360753B2 (no)
BR (1) BR0215360A (no)
CA (1) CA2470480C (no)
CO (1) CO5611126A2 (no)
DE (1) DE60205776T2 (no)
DK (1) DK1458713T3 (no)
ES (1) ES2247411T3 (no)
HK (1) HK1068886A1 (no)
HU (1) HUP0500111A3 (no)
IL (1) IL162203A0 (no)
MX (1) MXPA04006271A (no)
NO (1) NO327550B1 (no)
NZ (1) NZ533219A (no)
PL (1) PL208283B1 (no)
RU (1) RU2316554C2 (no)
WO (1) WO2003057690A1 (no)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7195876B2 (en) * 2002-08-09 2007-03-27 Theravance, Inc. Oncokinase fusion polypeptides associated with hyperproliferative and related disorders, nucleic acids encoding the same and methods for detecting and identifying the same
RU2006117635A (ru) * 2003-10-24 2007-12-10 Шеринг Акциенгезельшафт (De) Производные индолинона и их применение для лечения патологических состояний, таких как злокачественное новообразование
US20050171182A1 (en) * 2003-12-11 2005-08-04 Roger Briesewitz Methods and compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases
SE0401790D0 (sv) * 2004-07-07 2004-07-07 Forskarpatent I Syd Ab Tamoxifen response in pre- and postmenopausal breast cancer patients
US8071768B2 (en) 2005-06-10 2011-12-06 Janssen Pharmaceutica, N.V. Alkylquinoline and alkylquinazoline kinase modulators
US20060281788A1 (en) 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
US7825244B2 (en) 2005-06-10 2010-11-02 Janssen Pharmaceutica Nv Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis
NZ595182A (en) 2005-10-18 2012-12-21 Janssen Pharmaceutica Nv Pharmaceutical uses of 4-cyano-1H-imidazole-2-carboxylic acid { 2-cyclohex-1-enyl-4-[1-(2-dimethylamino-acetyl)-piperidin-4-yl]-phenyl} -amide
US8697716B2 (en) 2006-04-20 2014-04-15 Janssen Pharmaceutica Nv Method of inhibiting C-KIT kinase
RU2475483C2 (ru) 2006-04-20 2013-02-20 Янссен Фармацевтика Н.В. Ингибиторы с-fms киназы
WO2007124316A1 (en) 2006-04-20 2007-11-01 Janssen Pharmaceutica N.V. Heterocyclic compounds as inhibitors of c-fms kinase
CA2663147A1 (en) 2006-09-11 2008-03-20 Curis, Inc. Substituted 2-indolinone as ptk inhibitors containing a zinc binding moiety
JO3240B1 (ar) 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv c-fms مثبطات كيناز
FR2948940B1 (fr) * 2009-08-04 2011-07-22 Servier Lab Nouveaux derives dihydroindolones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP2521782B1 (en) 2010-01-05 2019-04-10 INSERM - Institut National de la Santé et de la Recherche Médicale Flt3 receptor antagonists for the treatment or the prevention of pain disorders
EP2523952B1 (en) 2010-01-12 2015-03-04 AB Science Oxazole kinase inhibitors
JOP20180012A1 (ar) 2012-08-07 2019-01-30 Janssen Pharmaceutica Nv عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد
IN2015DN00659A (no) 2012-08-07 2015-06-26 Janssen Pharmaceutica Nv
TWI569799B (zh) 2012-09-21 2017-02-11 安羅格製藥股份有限公司 抑制組成型活性磷酸化ｆｌｔ３激酶的方法
BR112015016282A2 (pt) 2013-01-07 2017-07-11 Arog Pharmaceuticals Inc crenolanibe para tratamento de distúrbios proliferativos de flt3 mutado
FR3008411B1 (fr) * 2013-07-12 2015-07-03 Servier Lab Nouveau sel de la 3-[(3-{[4-(4-morpholinylmethyl)-1h-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1h-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione, sa preparation, et les formulations qui le contiennent
US10463658B2 (en) 2013-10-25 2019-11-05 Videra Pharmaceuticals, Llc Method of inhibiting FLT3 kinase
US10065937B2 (en) 2014-07-31 2018-09-04 Inserm (Institut National De La Sante Et De La Recherche Medicale) FLT3 receptor antagonists
EP3254698A1 (en) 2016-06-08 2017-12-13 Universite De Montpellier Flt3 receptor inhibitor at low dosage for the treatment of neuropathic pain
US11078541B2 (en) 2016-11-02 2021-08-03 Arog Pharmaceuticals, Inc. Crenolanib for treating FLT3 mutated proliferative disorders associated mutations
WO2018211018A1 (en) 2017-05-17 2018-11-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Flt3 inhibitors for improving pain treatments by opioids
WO2019057649A1 (en) 2017-09-19 2019-03-28 INSERM (Institut National de la Santé et de la Recherche Médicale) METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA
US11713310B2 (en) 2020-07-20 2023-08-01 Arog Pharmaceuticals, Inc. Crystal forms of crenolanib and methods of use thereof
US11969420B2 (en) 2020-10-30 2024-04-30 Arog Pharmaceuticals, Inc. Combination therapy of crenolanib and apoptosis pathway agents for the treatment of proliferative disorders

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
CO5031249A1 (es) * 1998-05-29 2001-04-27 Sugen Inc Pirrol substituido-2-indolinonas inhibidoras de proteinci-nasas
PT1157019E (pt) * 1998-12-17 2003-06-30 Hoffmann La Roche 4-alcenil (e alcinil) oxindolos como inibidores dequinases dependentes de ciclina em particular cdk2
WO2000038519A1 (en) 1998-12-31 2000-07-06 Sugen, Inc. 3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activity and for use in cancer chemotherapy
DE19924401A1 (de) 1999-05-27 2000-11-30 Boehringer Ingelheim Pharma Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
CA2381821A1 (en) 1999-08-27 2001-03-08 Boehringer Ingelheim Pharma Kg Substituted indolinones, their manufacture and their use as medicaments
ATE277044T1 (de) 1999-10-06 2004-10-15 Boehringer Ingelheim Pharma Heterocyclische verbindungen verwendbar als tyrosinkinase inhibitoren
UA75054C2 (uk) 1999-10-13 2006-03-15 Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг Заміщені в положенні 6 індолінони, їх одержання та їх застосування як лікарського засобу
DE19949209A1 (de) 1999-10-13 2001-04-19 Boehringer Ingelheim Pharma In 5-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
AU2576501A (en) 1999-12-08 2001-06-18 Advanced Medicine, Inc. Protein kinase inhibitors
SK287142B6 (sk) 2000-02-15 2010-01-07 Sugen, Inc. Inhibítory proteínkináz na báze pyrolom substituovaného 2-indolinónu, farmaceutický prípravok s ich obsahom a ich použitie
CA2414468A1 (en) 2000-06-30 2002-01-10 Sugen, Inc. 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors
EA005809B1 (ru) 2000-08-18 2005-06-30 Милленниум Фармасьютикалз, Инк. Производные хиназолина в качестве ингибиторов киназы
US6677368B2 (en) 2000-12-20 2004-01-13 Sugen, Inc. 4-aryl substituted indolinones
US7195876B2 (en) 2002-08-09 2007-03-27 Theravance, Inc. Oncokinase fusion polypeptides associated with hyperproliferative and related disorders, nucleic acids encoding the same and methods for detecting and identifying the same
US20050171182A1 (en) 2003-12-11 2005-08-04 Roger Briesewitz Methods and compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases

Also Published As

Publication number Publication date
US6686362B2 (en) 2004-02-03
KR20040070283A (ko) 2004-08-06
KR100965519B1 (ko) 2010-06-23
DK1458713T3 (da) 2005-10-31
CA2470480A1 (en) 2003-07-17
CN1608063A (zh) 2005-04-20
BR0215360A (pt) 2004-12-14
ATE302771T1 (de) 2005-09-15
HUP0500111A3 (en) 2009-10-28
DE60205776T2 (de) 2006-06-14
CO5611126A2 (es) 2006-02-28
HUP0500111A2 (hu) 2005-07-28
MXPA04006271A (es) 2004-10-04
NO327550B1 (no) 2009-08-10
EP1458713A1 (en) 2004-09-22
US7223783B2 (en) 2007-05-29
AU2002360753A1 (en) 2003-07-24
CN1290844C (zh) 2006-12-20
IL162203A0 (en) 2005-11-20
US20030171378A1 (en) 2003-09-11
RU2316554C2 (ru) 2008-02-10
PL208283B1 (pl) 2011-04-29
ES2247411T3 (es) 2006-03-01
RU2004122918A (ru) 2005-03-27
NZ533219A (en) 2005-10-28
DE60205776D1 (en) 2005-09-29
PL369602A1 (en) 2005-05-02
US20040198804A1 (en) 2004-10-07
US7060703B2 (en) 2006-06-13
AU2002360753B2 (en) 2008-08-21
JP2005514420A (ja) 2005-05-19
US20060142281A1 (en) 2006-06-29
HK1068886A1 (en) 2005-05-06
CA2470480C (en) 2010-12-14
EP1458713B1 (en) 2005-08-24
WO2003057690A1 (en) 2003-07-17
JP4363985B2 (ja) 2009-11-11

Similar Documents

Publication Publication Date Title
NO20042926L (no) Indolinonderivater nyttige sorn proteinkinaseinhibitorer
CY1111599T1 (el) Αναστολεις κινασης θειενοπυριδινης και φουροπυριδινης
IL171976A0 (en) Indazole, benzisoxazole, and banzisothiazole kinase inhibitors
TW200621751A (en) Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors
MX2007001986A (es) Compuestos de aminoheteroarilo como inhibidores de proteina quinasa.
EA200901601A1 (ru) Производные пиридазинона
NO2010002I2 (no) Toceranibfosfat.
ATE554087T1 (de) Neue kinaseinhibitoren
DK1242382T3 (da) Tricycliske proteinkinaseinhibitorer
EA200901611A1 (ru) Производные 2-оксо-3-бензил-бензоксазол-2-она и родственные соединения в качестве ингибиторов мет киназы для лечения опухолей
CY1107475T1 (el) Αναστολεις ρο-κινασης
CA2366932A1 (en) Cyclic protein tyrosine kinase inhibitors
MXPA05013076A (es) Compuestos de isoindolina-1-ona como inhibidores de cinasa.
EA201000618A1 (ru) 5-цианотиенопиридины для лечения опухолей
BRPI0407841A (pt) inibidores heterocìclicos de quinase
PT1268472E (pt) Inibidores 3-aminopirazolicos de cinases dependentes da ciclina
ATE487721T1 (de) Triaza-benzoäeüazulenderivate zur behandlung von tumoren
DE60131968D1 (de) PYRANOÄ2,3-cÜIMIDAZOÄ1,2-aÜPYRIDIN-DERIVATE ZUR BEHANDLUNG VON GASTROINTESTINALEN ERKRANKUNGEN
DE60203740D1 (de) Luminacine analoge und deren verwendung
AU2002366563A1 (en) Certain glycine derivatives as factor xa inhibitors for use in the treatment of thrombotic disorders
UA86083C2 (en) Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors
ATE540951T1 (de) Substituierte 7,8-dihydro-1h-pyrimidoä4,5- büdiazepin-4-amine als kinase inhibitoren

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees